These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 28011961)
1. Genotypic analysis of HCV 1a by sequencing of the NS3 proteasic region in simeprevir therapy candidates. Liberti A; Raddi A; Cuomo N Infez Med; 2016 Dec; 24(4):272-277. PubMed ID: 28011961 [TBL] [Abstract][Full Text] [Related]
2. [Determination of drug resistance mutations of NS3 inhibitors in chronic hepatitis C patients infected with genotype 1]. Şanlıdağ T; Sayan M; Akçalı S; Kasap E; Buran T; Arıkan A Mikrobiyol Bul; 2017 Apr; 51(2):145-155. PubMed ID: 28566078 [TBL] [Abstract][Full Text] [Related]
4. Baseline prevalence and emergence of protease inhibitor resistance mutations following treatment in chronic HCV genotype-1-infected individuals. Nguyen LT; Gray E; Dean J; Carr M; Connell J; De Gascun C; Nguyen LA; O'Leary A; Bergin C; Hall W; Norris S Antivir Ther; 2015; 20(8):865-9. PubMed ID: 25920764 [TBL] [Abstract][Full Text] [Related]
5. Exploring resistance pathways for first-generation NS3/4A protease inhibitors boceprevir and telaprevir using Bayesian network learning. Cuypers L; Libin P; Schrooten Y; Theys K; Di Maio VC; Cento V; Lunar MM; Nevens F; Poljak M; Ceccherini-Silberstein F; Nowé A; Van Laethem K; Vandamme AM Infect Genet Evol; 2017 Sep; 53():15-23. PubMed ID: 28499845 [TBL] [Abstract][Full Text] [Related]
6. Prevalence of baseline NS3 resistance-associated substitutions (RASs) on treatment with protease inhibitors in patients infected with HCV genotype 1. Costa VD; Delvaux N; Brandão-Mello CE; Nunes EP; de Sousa PSF; de Souza Rodrigues LLLX; Lampe E; do Amaral Mello FC Clin Res Hepatol Gastroenterol; 2019 Nov; 43(6):700-706. PubMed ID: 30880098 [TBL] [Abstract][Full Text] [Related]
7. Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region. Sarrazin C; Lathouwers E; Peeters M; Daems B; Buelens A; Witek J; Wyckmans Y; Fevery B; Verbinnen T; Ghys A; Schlag M; Baldini A; De Meyer S; Lenz O Antiviral Res; 2015 Apr; 116():10-6. PubMed ID: 25614456 [TBL] [Abstract][Full Text] [Related]
8. Protease Inhibitors Drug Resistance Mutations in Turkish Patients with Chronic Hepatitis C. Sargin Altunok E; Sayan M; Akhan S; Aygen B; Yildiz O; Tekin Koruk S; Mistik R; Demirturk N; Ural O; Kose Ş; Aynioglu A; Korkmaz F; Ersoz G; Tuna N; Ayaz C; Karakecili F; Keten D; Inan D; Yazici S; Koculu S; Yildirmak T Int J Infect Dis; 2016 Sep; 50():1-5. PubMed ID: 27401586 [TBL] [Abstract][Full Text] [Related]
9. Baseline hepatitis C virus (HCV) NS3 polymorphisms and their impact on treatment response in clinical studies of the HCV NS3 protease inhibitor faldaprevir. Berger KL; Triki I; Cartier M; Marquis M; Massariol MJ; Böcher WO; Datsenko Y; Steinmann G; Scherer J; Stern JO; Kukolj G Antimicrob Agents Chemother; 2014; 58(2):698-705. PubMed ID: 24217701 [TBL] [Abstract][Full Text] [Related]
11. Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy. Vicenti I; Rosi A; Saladini F; Meini G; Pippi F; Rossetti B; Sidella L; Di Giambenedetto S; Almi P; De Luca A; Caudai C; Zazzi M J Antimicrob Chemother; 2012 Apr; 67(4):984-7. PubMed ID: 22258932 [TBL] [Abstract][Full Text] [Related]
12. NS3 protease polymorphism and natural resistance to protease inhibitors in French patients infected with HCV genotypes 1-5. Vallet S; Viron F; Henquell C; Le Guillou-Guillemette H; Lagathu G; Abravanel F; Trimoulet P; Soussan P; Schvoerer E; Rosenberg A; Gouriou S; Colson P; Izopet J; Payan C; Antivir Ther; 2011; 16(7):1093-102. PubMed ID: 22024525 [TBL] [Abstract][Full Text] [Related]
13. Predominance of hepatitis C virus Q80K among NS3 baseline-resistance-associated amino acid variants in direct-antiviral-agent-naïve patients with chronic hepatitis: single-centre experience. Ruggiero T; Proietti A; Boglione L; Milia MG; Allice T; Burdino E; Orofino G; Bonora S; Di Perri G; Ghisetti V Arch Virol; 2015 Nov; 160(11):2881-5. PubMed ID: 26249823 [TBL] [Abstract][Full Text] [Related]
14. Hepatitis C virus NS3 protease genotyping and drug concentration determination during triple therapy with telaprevir or boceprevir for chronic infection with genotype 1 viruses, southeastern France. Aherfi S; Solas C; Motte A; Moreau J; Borentain P; Mokhtari S; Botta-Fridlund D; Dhiver C; Portal I; Ruiz JM; Ravaux I; Bregigeon S; Poizot-Martin I; Stein A; Gérolami R; Brouqui P; Tamalet C; Colson P J Med Virol; 2014 Nov; 86(11):1868-76. PubMed ID: 25052594 [TBL] [Abstract][Full Text] [Related]
15. Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in Hepatitis C virus genotypes 1a, 2b and 3a. Palanisamy N; Danielsson A; Kokkula C; Yin H; Bondeson K; Wesslén L; Duberg AS; Lennerstrand J Antiviral Res; 2013 Jul; 99(1):12-7. PubMed ID: 23648709 [TBL] [Abstract][Full Text] [Related]
16. In Vitro Activity of Simeprevir against Hepatitis C Virus Genotype 1 Clinical Isolates and Its Correlation with NS3 Sequence and Site-Directed Mutants. Verbinnen T; Fevery B; Vijgen L; Jacobs T; De Meyer S; Lenz O Antimicrob Agents Chemother; 2015 Dec; 59(12):7548-57. PubMed ID: 26392483 [TBL] [Abstract][Full Text] [Related]
17. Pre-existing resistance associated polymorphisms to NS3 protease inhibitors in treatment naïve HCV positive Pakistani patients. Khan HU; Khan S; Shah MA; Attaullah S; Malik MA PLoS One; 2020; 15(4):e0231480. PubMed ID: 32275694 [TBL] [Abstract][Full Text] [Related]
18. Virology analyses of HCV genotype 4 isolates from patients treated with simeprevir and peginterferon/ribavirin in the Phase III RESTORE study. Fevery B; Verbinnen T; Peeters M; Janssen K; Witek J; Jessner W; De Meyer S; Lenz O J Viral Hepat; 2017 Jan; 24(1):28-36. PubMed ID: 27696653 [TBL] [Abstract][Full Text] [Related]
19. Resistance mutations are rare among protease inhibitor treatment-naive hepatitis C genotype-1 patients with or without HIV coinfection. Lisboa-Neto G; Noble CF; Pinho JR; Malta FM; Gomes-Gouvêa MS; Alvarado-Mora MV; da Silva MH; Leite AG; Piccoli LZ; Rodrigues FK; Carrilho FJ; Mendes-Correa MC Antivir Ther; 2015; 20(3):281-7. PubMed ID: 25279715 [TBL] [Abstract][Full Text] [Related]
20. Unexpected Replication Boost by Simeprevir for Simeprevir-Resistant Variants in Genotype 1a Hepatitis C Virus. Murai K; Shimakami T; Welsch C; Shirasaki T; Liu F; Kitabayashi J; Tanaka S; Funaki M; Omura H; Nishikawa T; Sumiyadorj A; Honda M; Kaneko S Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29661883 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]